RMDA: The Pharma Growth Engine 💊🚀
The Driver: High-margin growth in chronic treatments.
Revenue hit EGP 3.95B with steady institutional backing. 📈💰
Sharia Status: ✅ Compliant. A stable member of the EGX33 Shariah Index. ☪️📜
The Valuation: Trades at a premium P/E (~21x), reflecting its faster expansion vs. peers. 💎📊
The Technicals:
the 3.79 EGP level (61.8% Fibonacci). This is the last line of defense for the medium-term bullish structure. 📏🛡️
If 3.79 fails, the price is likely headed for a "Mean Reversion" at the 200-day Moving Average (at 3.4). 🧲📉
The Risk: Vulnerable to API import costs and currency-driven margin squeezes. ⚠️🏗️
If you like my posts, please follow and boost 🙌
The Driver: High-margin growth in chronic treatments.
Revenue hit EGP 3.95B with steady institutional backing. 📈💰
Sharia Status: ✅ Compliant. A stable member of the EGX33 Shariah Index. ☪️📜
The Valuation: Trades at a premium P/E (~21x), reflecting its faster expansion vs. peers. 💎📊
The Technicals:
the 3.79 EGP level (61.8% Fibonacci). This is the last line of defense for the medium-term bullish structure. 📏🛡️
If 3.79 fails, the price is likely headed for a "Mean Reversion" at the 200-day Moving Average (at 3.4). 🧲📉
The Risk: Vulnerable to API import costs and currency-driven margin squeezes. ⚠️🏗️
If you like my posts, please follow and boost 🙌
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
